RayKnowChina Research Map
Shortlist

Not yet recruitingBreast cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

Adding Preoperative Radiotherapy Based on Early Treatment Response in Breast Cancer

An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Second Affiliated Hospital, Zhejiang University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorSecond Affiliated Hospital, Zhejiang University浙江大学医学院附属第二医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07892508, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. 2. Histologically confirmed unilateral invasive breast cancer with documented estrogen receptor, progesterone receptor, HER2, and Ki-67 status.

    Inclusion criterion 2

    6. Suspicious or confirmed involved regional lymph nodes have undergone protocol-required pathological confirmation and marking when applicable.

    Inclusion criterion 6

  3. 4. Nonmetastatic disease on a curative-intent pathway; clinical stage cT1c to cT4c and cN0 to cN3, excluding cT4d inflammatory breast cancer.

    Inclusion criterion 4

  4. 3. No prior systemic therapy, radiotherapy, or definitive surgery for the current breast cancer.

    Inclusion criterion 3

    2. Prior radiotherapy to the ipsilateral breast, chest wall, or regional lymph nodes when cumulative dose constraints cannot be met.

    Exclusion criterion 2

  5. 5. At least one measurable breast primary tumor with a longest diameter of 15 mm or greater on baseline contrast-enhanced MRI; paired baseline BSGI and required lesion marking completed. Multifocal or multicentric disease must meet protocol imaging requirements.

    Inclusion criterion 5

    8. Able and willing to comply with MRI, BSGI, treatment, follow-up, and contraception requirements. Participants of childbearing potential must have a negative pregnancy test before examinations involving a radiopharmaceutical.

    Inclusion criterion 8

  6. 1. Distant metastatic disease, inflammatory breast cancer, or bilateral breast cancer requiring simultaneous definitive treatment.

    Exclusion criterion 1

  7. 4. Pregnancy or breastfeeding, or inability to implement required contraception.

    Exclusion criterion 4

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: day-to-day activity level; blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07892508, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • 1.Age 18 to 75 years at the time of written informed consent.
  • 2. Histologically confirmed unilateral invasive breast cancer with documented estrogen receptor, progesterone receptor, HER2, and Ki-67 status.
  • 3. No prior systemic therapy, radiotherapy, or definitive surgery for the current breast cancer.
  • 4. Nonmetastatic disease on a curative-intent pathway; clinical stage cT1c to cT4c and cN0 to cN3, excluding cT4d inflammatory breast cancer.
  • 5. At least one measurable breast primary tumor with a longest diameter of 15 mm or greater on baseline contrast-enhanced MRI; paired baseline BSGI and required lesion marking completed. Multifocal or multicentric disease must meet protocol imaging requirements.
  • 6. Suspicious or confirmed involved regional lymph nodes have undergone protocol-required pathological confirmation and marking when applicable.
  • 7. ECOG performance status 0 or 1 and organ function adequate for planned systemic therapy, radiotherapy, and surgery.
  • 8. Able and willing to comply with MRI, BSGI, treatment, follow-up, and contraception requirements. Participants of childbearing potential must have a negative pregnancy test before examinations involving a radiopharmaceutical.
  • 9. A guideline-recommended, curative-intent neoadjuvant systemic therapy plan has been documented before entry. HER2-positive disease includes anti-HER2 therapy, and at least six cycles or the regimen-defined complete course is planned.

Exclusion Criteria:

  • 1. Distant metastatic disease, inflammatory breast cancer, or bilateral breast cancer requiring simultaneous definitive treatment.
  • 2. Prior radiotherapy to the ipsilateral breast, chest wall, or regional lymph nodes when cumulative dose constraints cannot be met.
  • 3. Active infection, interstitial lung disease, or another condition making planned standard therapy, research radiotherapy, or surgery unacceptably risky. Active autoimmune disease or organ transplantation is exclusionary only when contraindicated by the planned systemic-therapy component or considered an unacceptable risk by the multidisciplinary team.
  • 4. Pregnancy or breastfeeding, or inability to implement required contraception.
  • 5. Inability, in the investigator's judgment, to complete definitive surgery or key follow-up procedures.

Quoted from ClinicalTrials.gov, NCT07892508, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07892508, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07892508